Gilotrif (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

GlobalData
June 30, 2013
71 Pages - SKU: GBDT5115041


Gilotrif (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Gilotrif (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Summary

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

Gilotrif is an irreversible inhibitor of the ErbB family of receptors, which include EGFR and HER2, and it has TKI activity against the wild-type as well as the mutant EGFR receptor. This distinguishes it from Tarceva and Iressa, which are reversible TKIs that only target the mutant receptor. Boehringer Ingelheim received FDA marketing approval for Gilotrif in July 2013 for the first-line treatment of EGFR-mutant NSCLC patients.

Scope
  • Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Gilotrif including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Gilotrif for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Gilotrif performance
  • Obtain sales forecast for Gilotrif from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China)


Additional Information



Country

Global

Sector

Oncology

Additional Details

Executive Summary

Sales for Gilotrif in the Global NSCLC MarketGilotrif sales are expected to increase from$53.28m upon launch in 2013 to $688.10m in 2022from sales in the seven major markets, China, andIndia.

Key factors affecting the uptake of Gilotrif willinclude:

Gilotrif will expand into the second-linetreatment of EGFR-mutant patients in 2014where it may gain patient shares of TKIresistantpatients

Significantly extends PFS over chemotherapyin the first-line treatment of EGFR-positivepatients

Gilotrif’s convenient daily oral dosing scheduleand less price will give advantage overonartuzumab and Tarceva therapy

Gilotrif will face intense competition with wellestablisheddrugs like Tarceva and Iressa inthe first line patient segment.

Gilotrif’s comparatively poor safety profile thenit’s major competitors

In the second-line, Gilotrif will compete againstRoche’s combination of onartuzumab andTarceva to delay or prevent TKI resistance aswell as Pfizer’s dacomitinib.

More Oncology/Hematology reports by GlobalData

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 by GlobalData
OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018SummaryChronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the ...
Cancer Anorexia Global Clinical Trials Review, H1, 2014 by GlobalData
Cancer Anorexia Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, “Cancer Anorexia Global Clinical Trials Review, H1, 2014 provides data on the Cancer Anorexia ...
Squamous Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014 by GlobalData
Squamous Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, “Squamous Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014 ...
Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2014 by GlobalData
Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, “Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2014 provides data on the ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 3,495  
    Site License  USD 6,990  
    Global Site License  USD 10,485  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!